<DOC>
	<DOCNO>NCT01034137</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study compare efficacy regard sustain remission safety tocilizumab methotrexate , combination monotherapy , treatment-naïve patient early rheumatoid arthritis . Patients randomize receive either tocilizumab ( 8mg/kg iv every 4 week ) plus weekly methotrexate ( po ascend dos ) , tocilizumab ( 8mg/kg iv every 4 week ) plus placebo , methotrexate plus placebo . Anticipated time study treatment 2 year , target sample size 300 .</brief_summary>
	<brief_title>A Study Tocilizumab Methotrexate Combination Monotherapy Treatment-Naïve Patients With Early Rheumatoid Arthritis</brief_title>
	<detailed_description>Multi-center , randomize , double-blind , placebo-controlled ( double placebo ) three-arm parallel group , comparative study . Patients randomize 1:1:1 ratio one follow treatment : - TCZ 8 milligram ( mg ) /kilogram ( kg ) + MTX ( Group I : TCZ+MTX ) - TCZ 8 mg/kg + placeboMTX ( Group II : TCZ+placebo ) - MTX + placeboTCZ ( Group III : MTX+placebo ) Randomization stratify participate center baseline Disease Activity Score , score 28 joint ( DAS28 ) level ( &lt; 5.1 vs. ≥5.1 ) . Patients evaluate every 4 week visit decision dosage change make base efficacy parameter ( DAS28 ) occurrence adverse event ( AEs ) . Patients receive MTX/placeboMTX climb dosage . Hydroxychloroquine ( HCQ ) add remission reach maximum tolerable dosage ( MTD ) MTX/placeboMTX . If 12 additional week remission reach , HCQ stop replace standard care therapy ( Group I ) placebo therapy replace correspond verum result TCZ+MTX combination therapy ( Groups II III ) . In case remission reach , MTX/placeboMTX TCZ/placeboTCZ decrease . Patients follow maximum 24 month</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , &gt; /=18 year age early rheumatoid arthritis ( disease symptom &lt; 1 year ) accord ACR criterion disease activity DAS28 &gt; 2.6 body weight &lt; /=110kg , BMI &lt; /=36 rheumatic autoimmune disease RA current inflammatory joint disease RA previous treatment DMARD biologic drug use treatment RA intraarticular , parenteral oral glucocorticoid use arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Treat-to-target , tight control , strategy study , TCZ , MTX</keyword>
</DOC>